Search clinical trials for: Placebo (NNC0519-0130)

Total 54128 results

Novo Nordisk A/S

Completed

A Research Study of a New Medicine NNC0519-0130 in Healthy People, People With High Body Weight and People With Type 2 Diabetes.

Healthy Volunteers (Diabetes Mellitus, Type 2)

Germany, Denmark
Novo Nordisk A/S

Completed

A Research Study of a New Medicine NNC0519-0130 in Japanese and Non-Japanese Men

Diabetes Mellitus, Type 2

Japan
Novo Nordisk A/S

Recruiting

A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Korea, Republic of, India, Australia, Canada, Japan, South Africa
Novo Nordisk A/S

Recruiting

A Research Study Looking Into Blood Levels of the Medicine NNC0519-0130 in the Body in Participants With Normal or Reduced Kidney Function

Diabetes Mellitus, Type 2

Germany
Novo Nordisk A/S

Recruiting

A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose Weight

Obesity

United States, Australia, Japan
Novo Nordisk A/S

Recruiting

A First Human Dose Study Investigating Safety and Concentration of Study Medicine in the Blood Following Once Daily Oral Dosing of NNC0560-0004 in Healthy Adults.

Healthy Volunteers - Liver Diseases

United Kingdom
Novo Nordisk A/S

Completed

First Research Study of the Possible New Medicine NNC0113-2023 in Healthy Men.

Diabetes Mellitus, Type 2

United States
Novo Nordisk A/S

Recruiting

A Study to Look at Safety and Tolerability of NNC0582-0001, How it is Transported Throughout the Body and How it Works in Healthy Adults

Healthy Volunteers

Austria
Novo Nordisk A/S

Completed

A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy of NNC0114-0006 in Subjects With Active Rheumatoid Arthritis

Inflammation | Rheumatoid Arthritis

Spain, Hungary, Serbia, Bulgaria, Poland, Russian Federation, Latvia
Novo Nordisk A/S

Completed

Investigation on Safety, Tolerability and Pharmacokinetics of Multiple Doses of NNC0113-0987 in an Oral Formulation in Healthy Subjects

Healthy | Diabetes

Germany
Novo Nordisk A/S

Active, not recruiting

A Research Study to Look at How a New Medicine Called NNC6019-0001 Works and How Safe it is for People Who Have Heart Disease Due to Transthyretin (TTR) Amyloidosis

Transthyretin Amyloid Cardiomyopathy (ATTR CM)

United States, Netherlands, Spain, Portugal, Canada, Czechia, France, Germany, Italy, Japan
Novo Nordisk A/S

Completed

A Research Study Looking at How the Medicine NNC0194-0499 Behaves in Japanese and Non-Asian Men

Non-alcoholic Steatohepatitis

Japan
Novo Nordisk A/S

Completed

A Research Study of a New Medicine NNC0113-6856 in Healthy Males

Type 2 Diabetes | Healthy Volunteers

Germany
Novo Nordisk A/S

Completed

Investigation on Safety, Tolerability, and Pharmacokinetics of Single Doses of NNC0113-0987 in Healthy Male Subjects

Healthy | Diabetes Mellitus, Type 2 | Diabetes

United Kingdom
Novo Nordisk A/S

Completed

Safety and Tolerability of NNC0114-0006 at Increasing Dose Levels in Subjects With Rheumatoid Arthritis

Inflammation | Rheumatoid Arthritis

Russian Federation, Germany
Novo Nordisk A/S

Terminated

An Investigation of Safety and Tolerability of NNC0114-0006 in Subjects With Systemic Lupus Erythematosus (SLE)

Inflammation | Systemic Lupus Erythematosus

Serbia, Hungary, Poland, United States
Novo Nordisk A/S

Recruiting

Investigation of Safety, Tolerability and Pharmacokinetics of Multiple Doses of NNC0113-6856 in Healthy Participants, Including a Subset of Healthy Japanese Participants

Healthy Participants

Germany
Novo Nordisk A/S

Recruiting

A Study to Look at How Safe a New Medicine (NNC0491-6075) is in Healthy People and in Participants With High Levels of Fat in the Blood

Healthy Volunteers | Dyslipidaemia

United States
Novo Nordisk A/S

Completed

A Research Study Looking at a New Study Medicine (NNC0194-0499) for Weight Control in People With Overweight or Obesity

Obesity | Metabolism and Nutrition Disorder

United States
Novo Nordisk A/S

Terminated

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Inflammation | Rheumatoid Arthritis

United States, Mexico, France, Italy, Spain, Argentina, Belgium, Brazil, Czechia, Germany, Hungary, Poland, United Kingdom
Novo Nordisk A/S

Completed

First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0194-0499 in Male Subjects With Overweight or Obesity

Obesity | Metabolism and Nutrition Disorder

United States
Novo Nordisk A/S

Completed

A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease

Inflammation | Crohn's Disease

United States, Spain, Bulgaria, Czech Republic, Poland, Slovakia
Novo Nordisk A/S

Completed

A Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0215-0384 Administered to Subjects With Moderate to Severe Rheumatoid Arthritis

Inflammation | Rheumatoid Arthritis

Germany, Russian Federation, Poland, Hungary
Novo Nordisk A/S

Completed

A Study Investigating the Distribution and Metabolism of Three 14C-labeled Radioactive Study Compounds

Type 2 Diabetes | Healthy Volunteers

Netherlands
Novo Nordisk A/S

Completed

Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long Acting GLP-1 Analogue (NNC0113-0987) in Healthy Male Subjects

Healthy | Diabetes

United Kingdom
Novo Nordisk A/S

Completed

First-in-Man Trial of NNC114-0005 in Healthy Subjects and Subjects With Rheumatoid Arthritis

Inflammation | Healthy | Rheumatoid Arthritis

Germany
Novo Nordisk A/S

Recruiting

First Human Dose Trial for a New Medication to Potentially Treat Liver Diseases

Healthy Volunteers

United Kingdom
Novo Nordisk A/S

Completed

First Human Dose Trial of NNC0195-0092 (Somapacitan) in Healthy Subjects

Healthy | Growth Hormone Disorder | Growth Hormone Deficiency in Children | Adult Growth Hormone Deficiency

Germany
Contera Pharma
Bukwang Pharmaceutical

Active, not recruiting

A Study in Parkinson's Disease in Patients With Moderate to Severe Dyskinesia (ASTORIA)

Dyskinesias

France, Germany, Italy, Korea, Republic of, Spain
Hutchison Medipharma Limited

Completed

A Phase III Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer (FALUCA)

NSCLC

China
Novo Nordisk A/S

Completed

Trial to Compare the Efficacy and Safety of NNC0195-0092 (Somapacitan) With Placebo and Norditropin® FlexPro® (Somatropin) in Adults With Growth Hormone Deficiency. (REAL 1)

Growth Hormone Disorder | Adult Growth Hormone Deficiency

United States, Poland, India, Japan, Russian Federation, United Kingdom, Germany, Sweden, Israel, Malaysia, Turkey, South Africa, Australia, Latvia, Lithuania, Romania, Brazil, Norway, Ukraine
PurGenesis Technologies Inc.

Completed

A Study to Assess the Safety and Tolerability of PUR 0110 Rectal Enema in Normal Healthy Volunteers

Ulcerative Colitis

Germany
Hutchison Medipharma Limited
Sun Yat-sen University; Fudan University

Completed

Study of Fruquintinib in Patients With Metastatic Colorectal Cancer

Colorectal Cancer

China
Hutchison Medipharma Limited
Fudan University; Eighty-One Hospital of People's Liberation Army

Completed

A Phase III Trial Evaluating Fruquintinib Efficacy and Safety in 3+ Line Colorectal Cancer Patients （FRESCO) (FRESCO)

Colorectal Cancer

China
Hutchison Medipharma Limited
Shanghai Chest Hospital

Completed

A Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Metabolic Solutions Development Company

Completed

3-month Study of MSDC-0160 Effects on Brain Glucose Utilization, Cognition & Safety in Subjects With Alzheimer's Disease

Alzheimer's Disease

United States
Novo Nordisk A/S

Completed

A Trial Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Male and Female Subjects Being Overweight or With Obesity

Obesity | Metabolism and Nutrition Disorder

United States
Moerae Matrix, Inc.

Unknown

Phase 1a Study in Healthy Smokers to Investigate the Effect With MMI-0100 on Airway Inflammation in Induced Sputum After Challenge With Inhaled Lipopolysaccharide (LPS)

Acute Inflammatory Response to Non-antigenic Stimulus

United Kingdom
Novo Nordisk A/S

Completed

A Research Study Comparing Blood Levels of Medicines NNC0194-0499 and Semaglutide Administered as a Combination Formulation Versus Two Separate Formulations

Non-alcoholic Steatohepatitis

Canada
Novo Nordisk A/S

Recruiting

A Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 for People Who Have Heart Failure Due to Transthyretin Amyloidosis

Transthyretin Amyloid Cardiomyopathy (ATTR CM)

United States, Netherlands, Germany, Canada, Czechia, France, Italy, Portugal, Spain
Novo Nordisk A/S

Completed

A Research Study Looking Into Blood and Urine Levels of the Medicine NNC0194-0499 in the Body and How Well it is Tolerated in Participants With Reduced Kidney Function and Normal Kidney Function

Non-alcoholic Steatohepatitis (NASH)

Germany
BioMimetix JV, LLC

Completed

Topical Application of BMX-010 in Subjects With Atopic Dermatitis and Plaque Psoriasis

Psoriasis | Atopic Dermatitis

United States
Innate Pharma

Completed

Safety and Tolerability of NNC0141-0000-0100 in Subjects With Rheumatoid Arthritis

Inflammation | Rheumatoid Arthritis

Germany
PurGenesis Technologies Inc.

Completed

Safety, Tolerability, Efficacy Study of PUR 0110 Rectal Enema in Mild-to-Moderate Distal Ulcerative Colitis

Left-Sided Ulcerative Colitis | Proctosigmoiditis

Germany
ImmunoRx Pharma Inc.

Recruiting

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Intravenous Administration of IRX-010 in Healthy Participants

Healthy Participants

Netherlands
BioMimetix JV, LLC
Innovaderm Research Inc.

Terminated

A Clinical Trial of BMX-010 in Adult Subjects With Atopic Dermatitis

Atopic Dermatitis

United States
Afferent Pharmaceuticals, Inc.

Completed

A Pharmacokinetics Study of AF-130 in Healthy Subjects

Healthy Volunteers

United Kingdom
Novo Nordisk A/S

Terminated

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate

Inflammation | Rheumatoid Arthritis

United States, Mexico, Russian Federation, France, Italy, Spain, Argentina, Belgium, Brazil, Czechia, Germany, Poland, Ukraine, Hungary
GeneOne Life Science, Inc.

Not yet recruiting

GLS-5310 Vaccine in Healthy Volunteers for the Prevention of SARS-CoV-2 (COVID-19)

Healthy | Covid19

Puerto Rico
KinoPharma Inc.

Active, not recruiting

OM202JP Clinical Study of KNP2002

Common Wart

Japan

3

Subscribe